Last reviewed · How we verify

Trilisate — Competitive Intelligence Brief

Trilisate (CHOLINE MAGNESIUM TRISALICYLATE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: choline magnesium trisalicylate. Area: Immunology.

discontinued choline magnesium trisalicylate Immunology Live · refreshed every 30 min

Target snapshot

Trilisate (CHOLINE MAGNESIUM TRISALICYLATE). Trilisate works by blocking the production of prostaglandins, hormone-like substances that cause pain and inflammation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Trilisate TARGET CHOLINE MAGNESIUM TRISALICYLATE discontinued choline magnesium trisalicylate

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (choline magnesium trisalicylate class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trilisate — Competitive Intelligence Brief. https://druglandscape.com/ci/choline-magnesium-trisalicylate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: